Intuitive Surgical, Inc. (NASDAQ:ISRG) EVP Brian Edward Miller Sells 2,553 Shares

Intuitive Surgical, Inc. (NASDAQ:ISRG) EVP Brian Edward Miller sold 2,553 shares of Intuitive Surgical stock in a transaction that occurred on Tuesday, October 22nd. The stock was sold at an average price of $515.00, for a total value of $1,314,795.00. Following the completion of the sale, the executive vice president now owns 7,066 shares of the company’s stock, valued at approximately $3,638,990. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Intuitive Surgical Trading Down 1.0 %

NASDAQ ISRG opened at $512.58 on Thursday. The business has a fifty day simple moving average of $486.71 and a 200 day simple moving average of $440.96. Intuitive Surgical, Inc. has a 12 month low of $254.85 and a 12 month high of $523.34. The firm has a market capitalization of $181.81 billion, a P/E ratio of 92.52, a PEG ratio of 5.40 and a beta of 1.39.

Wall Street Analyst Weigh In

ISRG has been the subject of several research analyst reports. JPMorgan Chase & Co. lifted their price objective on shares of Intuitive Surgical from $495.00 to $575.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. Redburn Atlantic raised shares of Intuitive Surgical from a “neutral” rating to a “buy” rating and lifted their price target for the company from $380.00 to $510.00 in a research note on Friday, August 2nd. Leerink Partners upped their price objective on shares of Intuitive Surgical from $489.00 to $502.00 in a report on Thursday, October 17th. BTIG Research set a $535.00 target price on Intuitive Surgical in a research note on Friday, October 18th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $538.00 price target (up from $495.00) on shares of Intuitive Surgical in a research note on Friday, October 18th. One analyst has rated the stock with a sell rating, five have issued a hold rating and fourteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $513.74.

Institutional Trading of Intuitive Surgical

Several institutional investors have recently made changes to their positions in ISRG. Ullmann Wealth Partners Group LLC grew its position in Intuitive Surgical by 1.6% in the 3rd quarter. Ullmann Wealth Partners Group LLC now owns 1,329 shares of the medical equipment provider’s stock worth $653,000 after purchasing an additional 21 shares in the last quarter. One Wealth Management Investment & Advisory Services LLC lifted its holdings in Intuitive Surgical by 3.4% during the second quarter. One Wealth Management Investment & Advisory Services LLC now owns 697 shares of the medical equipment provider’s stock worth $310,000 after acquiring an additional 23 shares during the period. Daymark Wealth Partners LLC boosted its position in Intuitive Surgical by 0.3% in the third quarter. Daymark Wealth Partners LLC now owns 7,027 shares of the medical equipment provider’s stock worth $3,452,000 after purchasing an additional 24 shares during the last quarter. Indiana Trust & Investment Management CO grew its stake in Intuitive Surgical by 5.3% in the 2nd quarter. Indiana Trust & Investment Management CO now owns 500 shares of the medical equipment provider’s stock valued at $222,000 after purchasing an additional 25 shares during the period. Finally, Hoxton Planning & Management LLC increased its position in shares of Intuitive Surgical by 4.9% during the 2nd quarter. Hoxton Planning & Management LLC now owns 534 shares of the medical equipment provider’s stock valued at $238,000 after purchasing an additional 25 shares during the last quarter. Institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.